Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014).
Shi, H., Wei, J. & He, C. Where, when, and how: Context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell 74, 640–650 (2019).
Chen, Y. et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol. Cancer 18, 127 (2019).
Chen, S. et al. WTAP promotes osteosarcoma tumorigenesis by repressing HMBOX1 expression in an m(6)A-dependent manner. Cell Death Dis. 11, 659 (2020).
Li, Q., Wang, C., Dong, W., Su, Y. & Ma, Z. WTAP facilitates progression of endometrial cancer via CAV-1/NF-kappaB axis. Cell Biol. Int. 45, 1269–1277 (2021).
Li, H. et al. High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration. J. Cell. Mol. Med. 24, 4452–4465 (2020).
Yu, H. L. et al. WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. Onco Targets Ther. 12, 6191–6201 (2019).
Chen, L. & Wang, X. Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis. Oncol. Lett. 16, 6966–6970 (2018).
Wu, L. S., Qian, J. Y., Wang, M. & Yang, H. Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses. Mol. Med. Rep. 14, 2823–2831 (2016).
Wu, L., Wu, D., Ning, J., Liu, W. & Zhang, D. Changes of N6-methyladenosine modulators promote breast cancer progression. BMC Cancer 19, 326 (2019).
Zeng, Y. et al. Combined high resistin and EGFR expression predicts a poor prognosis in breast cancer. Biomed. Res. Int. 2020, 8835398 (2020).
Elston, C. W. & Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19, 403–410 (1991).
Paltoglou, S. et al. Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer. Cancer Res. 77, 3417–3430 (2017).
Liang, H., Lin, Z., Ye, Y., Luo, R. & Zeng, L. ARRB2 promotes colorectal cancer growth through triggering WTAP. Acta Biochim. Biophys. Sin. 53, 85–93 (2021).
Xue, C. et al. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci. 103, 1679–1687 (2012).
Ugras, S., Stempel, M., Patil, S. & Morrow, M. Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann. Surg. Oncol. 21, 3780–3786 (2014).
Mazouni, C. et al. Outcome in breast molecular subtypes according to nodal status and surgical procedures. Am. J. Surg. 205, 662–667 (2013).
Si, C., Jin, Y., Wang, H. & Zou, Q. Association between molecular subtypes and lymph node status in invasive breast cancer. Int. J. Clin. Exp. Pathol. 7, 6800–6806 (2014).
Kim, M. J. et al. Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum. Pathol. 37, 1217–1226 (2006).
Lakhani, S. R. E. I., Schnitt, S. J., Tan, P. H. & van de Vijver, M. J. WHO Classification of Tumours of the Breast 4th edn. (IARC Press, 2012).
Yang, W. T. & Bu, H. Updates in the 5(th) edition of WHO classification of tumours of the breast. Zhonghua Bing Li Xue Za Zhi 49, 400–405 (2020).
Park, S. et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 21, 50–57 (2012).
Wang, C. Q. et al. Fascin-1 as a novel diagnostic marker of triple-negative breast cancer. Cancer Med. 5, 1983–1988 (2016).
Wang, C. Q. et al. EGFR conjunct FSCN1 as a novel therapeutic strategy in triple-negative breast cancer. Sci. Rep. 7, 15654 (2017).
Dong, X. F. et al. Downregulated METTL14 expression correlates with breast cancer tumor grade and molecular classification. Biomed. Res. Int. 2020, 8823270 (2020).
Wang, C. Q. et al. High expression of both resistin and fascin-1 predicts a poor prognosis in patients with colorectal cancer. Biomed. Res. Int. 2020, 8753175 (2020).
Wang, C. Q. et al. Expression of HMGB1 protein in breast cancer and its clinicopathological significance. Zhonghua Bing Li Xue Za Zhi 49, 57–61 (2020).
Nguyen, T. H., Nguyen, V. H., Nguyen, T. L., Qiuyin, C. & Phung, T. H. Evaluations of biomarker status changes between primary and recurrent tumor tissue samples in breast cancer patients. Biomed. Res. Int. 2019, 7391237 (2019).
Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105–2122 (2018).